<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Med Case Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">J Med Case Rep</journal-id>
<journal-title-group>
<journal-title>Journal of Medical Case Reports</journal-title>
</journal-title-group>
<issn pub-type="epub">1752-1947</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30249282</article-id>
<article-id pub-id-type="pmc">6154911</article-id>
<article-id pub-id-type="publisher-id">1788</article-id>
<article-id pub-id-type="doi">10.1186/s13256-018-1788-7</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Novel in-frame deletion in <italic>MFSD8</italic> gene revealed by trio whole exome sequencing in an Iranian affected with neuronal ceroid lipofuscinosis type 7: a case report</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hosseini Bereshneh</surname>
<given-names>Ali</given-names>
</name>
<address>
<phone>+98 21 82884569</phone>
<email>a.hosseinibereshneh@modares.ac.ir</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Garshasbi</surname>
<given-names>Masoud</given-names>
</name>
<address>
<phone>+98 21 82884569</phone>
<email>masoud.garshasbi@modares.ac.ir</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1781 3962</institution-id><institution-id institution-id-type="GRID">grid.412266.5</institution-id><institution>Department of Medical Genetics, Faculty of Medical Sciences, </institution><institution>Tarbiat Modares University, </institution></institution-wrap>Tehran, Iran </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>25</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>25</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>12</volume>
<elocation-id>281</elocation-id>
<history>
<date date-type="received">
<day>2</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>7</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2018</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">The neuronal ceroid lipofuscinoses are a group of neurodegenerative, lysosomal storage disorders. They are inherited as an autosomal recessive pattern with the exception of adult neuronal ceroid lipofuscinosis, which can be inherited in either an autosomal recessive or an autosomal dominant manner. The neuronal ceroid lipofuscinoses are characterized by accumulation of autofluorescent lipopigments in the cells and one of the most important pathological manifestations is ceroid accumulation in the lysosomes. Various types of neuronal ceroid lipofuscinoses are categorized based on the clinical manifestations and the genes involved. Accumulatively, 15 different genes have been found so far to be implicated in the pathogenesis of at least nine different types of neuronal ceroid lipofuscinoses, which result in similar pathological and clinical manifestations.</p>
</sec>
<sec>
<title>Case presentation</title>
<p id="Par2">A 5-year-old Iranian boy affected by a neurodegenerative disorder with speech problems, lack of concentration, walking disability at age of 4 years leading to quadriplegia, spontaneous laughing, hidden seizure, clumsiness, psychomotor delay, and vision deterioration at age of 5 years, which could be the consequence of macular dystrophy, was referred to us for genetic testing. Trio whole exome sequencing, Sanger validation, and segregation analysis discovered a novel in-frame small deletion c.325_339del (p.Val109_Ile113del) in <italic>MFSD8</italic> gene associated with neuronal ceroid lipofuscinosis type 7.</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par3">The deletion found in this patient affects the exon 5 of this gene which is the region encoding transmembrane domain. Sequencing analysis in this family has shown that the index is homozygous for 15 base pairs in-frame deletion, his uncle has normal homozygous, and his parents are heterozygous. This pattern of mutation inheritance and the signs and symptoms observed in the affected male of this family are compatible with what is described in the literature for neuronal ceroid lipofuscinosis type 7 and, therefore, suggest that the <italic>MFSD8</italic> gene deletion found in this study is most probably the cause of disease in this family.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Neuronal ceroid lipofuscinosis type 7</kwd>
<kwd>N.eurodegenerative</kwd>
<kwd><italic>MFSD8</italic> gene</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par23">The neuronal ceroid lipofuscinoses (NCLs or CLNs), also called Batten disease, are a set of neurodegenerative genetic disorders with an overall frequency of 1 in 100,000 individuals around the world [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. This condition conforms to an autosomal recessive (AR) pattern of inheritance and is mainly caused by consanguineous marriage [<xref ref-type="bibr" rid="CR3">3</xref>]. Babies affected with these lysosomal storage diseases do not manifest any clinical symptoms at birth; however, signs and symptoms mostly begin before 7 years of age depending on the gene involved [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. These conditions are genetically heterogeneous and consist of a wide spectrum of phenotypical and clinical manifestations. NCLs are characterized by the accumulation of autofluorescent lipopigments in cells [<xref ref-type="bibr" rid="CR5">5</xref>] and one of the most important pathological manifestations is ceroid accumulation in lysosomes [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The accumulation of storage material in nerve cells results in massive neuronal loss and subsequent apoptosis, as has been shown in an autopsy of the brain [<xref ref-type="bibr" rid="CR7">7</xref>]. The categorization of various types of NCLs is based on the phenotype and the genes that are mutated. Accumulatively, mutation in at least 15 different genes has been shown to be implicated in the pathogenesis of at least nine different types of NCLs which result in a similar pathological and clinical manifestation; Table <xref ref-type="table" rid="Tab1">1</xref> [<xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR10">10</xref>]. Genes involved in the pathogenesis of NCLs are mainly affected by loss-of-function mutations [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Different types of neuronal ceroid lipofuscinosis</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Types of NCLs</th><th>Pattern</th><th>Onset</th><th>Gene</th><th>Chromosome location</th></tr></thead><tbody><tr><td>NCL1</td><td>AR</td><td>Infantile<break></break>Adulthood (mild form)</td><td><italic>PTT1</italic>/<italic>CLN1</italic></td><td>1p32</td></tr><tr><td>NCL2</td><td>AR</td><td>Late infantile</td><td><italic>TPP1</italic>/<italic>CLN2</italic></td><td>11p15.5</td></tr><tr><td>NCL3</td><td></td><td>Juvenile</td><td>
<italic>CLN3</italic>
</td><td>16p12.1</td></tr><tr><td>NCL4</td><td>AR<break></break>AD</td><td>Adulthood</td><td>
<italic>CLN6</italic>
<break></break>
<italic>DNAJC5</italic>
</td><td>15q21-q23<break></break>20q13.33</td></tr><tr><td>NCL5</td><td>AR</td><td>Late infantile<break></break>Adulthood (mild form)</td><td>
<italic>CLN5</italic>
</td><td>13q21.1-q32</td></tr><tr><td>NCL6</td><td>AR</td><td>Late infantile</td><td>
<italic>CLN6</italic>
</td><td>15q21.q23</td></tr><tr><td>NCL7</td><td>AR</td><td>Late infantile</td><td><italic>CLN7</italic>/<italic>MFSD8</italic></td><td>4q28.1-q28.2</td></tr><tr><td>NCL8</td><td>AR</td><td>Late infantile</td><td>
<italic>CLN8</italic>
</td><td>8p23.3</td></tr><tr><td>NCL9</td><td>AR</td><td>Juvenile</td><td>Unknown</td><td>Unknown</td></tr><tr><td>NCL10</td><td>AR</td><td>Newborn<break></break>Adulthood<break></break>(mild form)</td><td><italic>CLN10</italic>/<italic>CTSD</italic></td><td>1p15.5</td></tr></tbody></table><table-wrap-foot><p><italic>AD</italic> autosomal dominant, <italic>AR</italic> autosomal recessive, <italic>NCL</italic> neuronal ceroid lipofuscinosis</p></table-wrap-foot></table-wrap></p>
<p id="Par24">Phenotypically, there are three common different forms of NCLs; the categorization of these three forms of NCLs is mainly based on the age of onset: infantile NCL (INCL) that begins between 6 and 18 months of age; late INCL (LINCL) which begins at 2–4 years of age; and juvenile NCL (JNCL) which begins at the age of 6–10 years or sometimes in adulthood [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR15">15</xref>]. All types show overlapping sign and symptoms, mainly cognitive impairment, progressive neuronal degeneration, motor deficits, seizures, progressive visual deterioration, and blindness [<xref ref-type="bibr" rid="CR16">16</xref>]. Motor dysfunction could lead to subsequent quadriplegia [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. The genes involved in NCLs present similar clinical manifestations; so, the finding of genetic mutations may explain unclear clinical findings and distinguish between them [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p>
<p id="Par25">The most prevalent types of NCLs are NCL1, which is considered an infantile form, NCL2, which is considered a late infantile form, and NCL3, which is considered a juvenile form [<xref ref-type="bibr" rid="CR21">21</xref>]. NCL1 is the most common form of INCLs. At birth, a baby with NCL1 has normal development, but this process is lost and motor dysfunction leads to hypotonia [<xref ref-type="bibr" rid="CR22">22</xref>]. There is evident vision loss and seizure at approximately 1 year of age [<xref ref-type="bibr" rid="CR23">23</xref>]. Profound microcephaly is a usual finding and patients will usually die before they reach the age of 7 years. Mutation in the palmitoyl-protein thioesterase (<italic>PPT</italic>) gene which encodes a fatty acid cleavage lysosomal protein is the cause of NCL1. R122W (c.364A&gt;T) and R151X (c.451C&gt;T) are the most common mutations of the <italic>PTT</italic> gene and accounted for approximately 20% of mutations [<xref ref-type="bibr" rid="CR2">2</xref>]. NCL2, also called Jansky–Bielschowsky disease, in which almost the majority of affected patients’ manifestations begin at late infantile period of life, is caused by mutations in the <italic>CLN2</italic> gene which encodes tripeptidyl-peptidase 1 (TPP1) [<xref ref-type="bibr" rid="CR24">24</xref>]. NCL3 is the juvenile form of this disease and often diagnosed with retinitis pigmentosa and late onset seizures at the second decade of life [<xref ref-type="bibr" rid="CR25">25</xref>]. There are other various types of NCLs; some of these conform to an autosomal dominant pattern of inheritance (types of NCL4 which are caused by mutation in the <italic>DNAJC5</italic> gene). NCL10 is the most malignant form and the only type of NCL which affect newborns [<xref ref-type="bibr" rid="CR26">26</xref>–<xref ref-type="bibr" rid="CR28">28</xref>]. NCL7 is caused by mutations in the <italic>MFSD8</italic>/<italic>CLN7</italic> gene and is a LINCL type [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p>
</sec>
<sec id="Sec2">
<title>Case presentation</title>
<p id="Par26">A 5-year-old Iranian boy with a neurodegenerative disorder was referred for genetic testing. His clinical symptoms were speech problems, lack of concentration, walking disability at age of 4 years leading to quadriplegia, spontaneous laughing and crying because of hidden seizure, clumsiness, psychomotor delay, and vision deterioration at age of 5 years which could be the consequence of macular dystrophy. Brain magnetic resonance imaging (MRI) and electroencephalogram (EEG) showed bilateral white matter signal change with preservation of white matter (Fig. <xref ref-type="fig" rid="Fig1">1</xref> and Fig. <xref ref-type="fig" rid="Fig2">2</xref>). There are no available histopathological studies or skin biopsy for this patient.<fig id="Fig1"><label>Fig. 1</label><caption><p>Brain magnetic resonance imaging of patient</p></caption><graphic id="MO1" xlink:href="13256_2018_1788_Fig1_HTML"></graphic></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Brain electroencephalogram of patient</p></caption><graphic id="MO2" xlink:href="13256_2018_1788_Fig2_HTML"></graphic></fig></p>
<p id="Par27">The organic acids in his urine were determined using gas chromatography–mass spectrometry (GC-MS) of the trimethylsilyl ethers and esters of the ethyl acetate extract from acidified urine after preparation of the ethoxime derivatives. The organic acid in the urine of this patient showed a normal pattern with no evidence for metabolic disorders. There is no evidence for tyrosinemia, glutaric aciduria, methylmalonic aciduria, Canavan disease, propionic aciduria, isovaleric aciduria, and other organic aciduria known in Iran. Neonatal screening, clinical chemistry, and metabolism assays showed a normal pattern and these analyses were unremarkable (Table <xref ref-type="table" rid="Tab2">2</xref> and Table <xref ref-type="table" rid="Tab3">3</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Neonatal screening</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Assay</th><th>Result</th><th>Reference range</th></tr></thead><tbody><tr><td colspan="3">Neonatal screening</td></tr><tr><td> Thyroid-stimulating hormone (TSH)</td><td>&lt;  10 mU/l</td><td>&lt;  10 mU/l</td></tr><tr><td> 17-OH progesterone</td><td>&lt;  5 nmol/l</td><td>&lt;  5 nmol/l</td></tr><tr><td> Galactose (GAL; GAL-1-P)</td><td>&lt;  18 mg/dL</td><td>&lt;  18 mg/dL</td></tr><tr><td> Succinylacetone</td><td>&lt;  5 μmol/l</td><td>&lt;  5 μmol/l</td></tr><tr><td> GAL-1-P uridyltransferase</td><td>&gt;  20% activity</td><td>&gt;  20% activity</td></tr><tr><td> Biotinidase</td><td>&gt;  30% activity</td><td>&gt;  30% activity</td></tr><tr><td colspan="3">Disorder of amino acid metabolism</td></tr><tr><td colspan="3"> Amino acids (including phenyl.) TMS</td></tr><tr><td colspan="3">Disorders of beta oxidation of fatty acids</td></tr><tr><td> MCADD</td><td colspan="2">Unremarkable</td></tr><tr><td> VLCADD</td><td colspan="2">Unremarkable</td></tr><tr><td> LCHADD</td><td colspan="2">Unremarkable</td></tr><tr><td colspan="3">Disorders of carnitine metabolism</td></tr><tr><td> Acylcarnitines. TMS</td><td colspan="2">Unremarkable</td></tr><tr><td colspan="3">Disorders of organic acids</td></tr><tr><td> Isovalerylcarnitine</td><td colspan="2">Unremarkable</td></tr><tr><td> Glutaric acid</td><td colspan="2">Unremarkable</td></tr><tr><td colspan="3">Defects of urea cycle</td></tr><tr><td> Citrulline</td><td colspan="2">Unremarkable</td></tr><tr><td> Argininosuccinate</td><td colspan="2">Unremarkable</td></tr></tbody></table><table-wrap-foot><p><italic>act</italic>, <italic>Gal-1-P</italic> galactose-1-phosphate, <italic>LCHADD</italic> long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, <italic>MCADD</italic> medium-chain acyl-CoA dehydrogenase deficiency, <italic>phenyl</italic> phenylalanine, <italic>TMS</italic> tandem mass spectrometry, <italic>VLCADD</italic> very long-chain acyl-CoA dehydrogenase deficiency</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Clinical chemistry and metabolism assays</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Assay</th><th>Result</th><th>Reference range</th></tr></thead><tbody><tr><td>Creatinine</td><td>0.89 g/l</td><td>0.12–1.12 g/l</td></tr><tr><td>Docosanoic acid (C22)</td><td>45.8 nmol/ml</td><td>15–113 nmol/ml</td></tr><tr><td>Tetracosanoic acid (C24)</td><td>41.6 nmol/ml</td><td>12–94 nmol/ml</td></tr><tr><td>Hexacosanoic acid (C26)</td><td>0.4 nmol/ml</td><td>0.2–1.6 nmol/ml</td></tr><tr><td>C24/C22</td><td>0.91</td><td>0.55–1.05</td></tr><tr><td>C26/C22</td><td>0.009</td><td>0.005–0.029</td></tr><tr><td>Phytanic acid</td><td>3.2 nmol/ml</td><td>0.3–31 nmol/ml</td></tr><tr><td>Aryl sulfatase A</td><td>0.808 mu/mg</td><td>0.375–1.815</td></tr><tr><td>Aryl sulfatase B</td><td>1.654 mu/mg</td><td>0.722–3.749</td></tr></tbody></table></table-wrap></p>
<p id="Par28">Our patient’s parents are first cousins and had experienced three gestations, the first one aborted spontaneously before 4 weeks of pregnancy. The second one is the male reported here and the third one is a 2-year-old girl who does not manifest any signs and symptoms yet and seems to be normal. The pedigree is shown in Fig. <xref ref-type="fig" rid="Fig3">3</xref>.<fig id="Fig3"><label>Fig. 3</label><caption><p>Pedigree of family affected by neuronal ceroid lipofuscinosis. <italic># de novo</italic> or inherited deletion, <italic>+ heterozygous</italic> inferred from pedigree, <italic>* heterozygous</italic> confirmed by deletion analysis or Sanger sequencing. The <italic>arrow</italic> shows the proband in the family</p></caption><graphic id="MO3" xlink:href="13256_2018_1788_Fig3_HTML"></graphic></fig></p>
<p id="Par29">Deoxyribonucleic acid (DNA) was extracted from peripheral blood of our patient and his healthy parents. Whole exome sequencing (WES) was performed on all three samples as following. Approximately 37 mega base pairs (Mb; 214,405 exons) of the Consensus Coding Sequences (CCS) were enriched from fragmented genomic DNA by &gt; 340,000 probes designed against the human genome (Nextera Rapid Capture Exome, Illumina) and the generated library sequenced on an Illumina HiSeq 4000 platform (Illumina) to an average coverage depth of more than 100 × (Table <xref ref-type="table" rid="Tab4">4</xref>). An end-to-end bioinformatics pipeline including base calling, primary filtering of low quality reads and probable artifacts, and annotation of variants was applied. All disease-causing variants reported in HGMD® or ClinVar (class 1) as well as all variants with minor allele frequency (MAF) of less than 1% in Exome Aggregation Consortium (ExAC) database were considered. The evaluation focused on exons and intron boundaries +/− 20. All relevant inheritance patterns were considered and clinical information was used to evaluate eventually identified variants. Relevant variants identified by WES were validated by Sanger sequencing in forward and reverse direction. By applying different filtering steps mentioned in the method part we ended up with only two novel variants in <italic>MFSD8</italic> and <italic>AFF2</italic> genes (Table <xref ref-type="table" rid="Tab5">5</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Analysis statistics, average coverage and % target base pairs covered</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th></th><th colspan="6">% target bp covered</th></tr><tr><th></th><th>Average coverage (X)</th><th>0X</th><th>≥ 1X</th><th>≥ 5X</th><th>≥ 10X</th><th>≥ 20X</th><th>≥ 50X</th></tr></thead><tbody><tr><td>Index</td><td>111.69</td><td>0.17</td><td>99.83</td><td>99.34</td><td>98.57</td><td>96.51</td><td>85.37</td></tr><tr><td>Mother</td><td>101.42</td><td>0.33</td><td>99.67</td><td>98.95</td><td>97.98</td><td>95.36</td><td>82.09</td></tr><tr><td>Father</td><td>106.15</td><td>0.19</td><td>99.81</td><td>99.25</td><td>98.32</td><td>95.86</td><td>83.15</td></tr></tbody></table><table-wrap-foot><p><italic>bp</italic> base pairs</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table 5</label><caption><p>Results of trio whole exome sequencing and significant findings</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Gene (transcript)</th><th rowspan="2">Nucleotide (protein)</th><th colspan="3">Zygosity</th><th rowspan="2">Described by</th><th rowspan="2"><italic>In silico</italic> parameters*</th><th rowspan="2">MAF**</th><th rowspan="2">Variant classification***</th><th rowspan="2">Disorder (OMIM# inheritance)</th></tr><tr><th>Index</th><th>Mother</th><th>Father</th></tr></thead><tbody><tr><td>
<italic>AFF2</italic>
<break></break>(NM_002025.3)</td><td>c.259A&gt;G<break></break>(p.Asn87Asp)</td><td>Hem.</td><td>Het.</td><td>–</td><td>Not described</td><td>2/4 Damaging</td><td>Not<break></break>detected</td><td>Significance uncertain (class 3)</td><td><italic>AFF2</italic>-related X-linked mental retardation (309,548, XLR)</td></tr><tr><td>
<italic>MFSD8</italic>
<break></break>(NM_152778.2)</td><td>c.325_339del (p.Val109_Ile113del)</td><td>Hom.</td><td>Het.</td><td>Het.</td><td>Not described</td><td>In-frame small deletion</td><td>Not<break></break>detected</td><td>Significance uncertain (class 3)</td><td>Neuronal ceroid lipofuscinosis type 7(610,951, AR)</td></tr></tbody></table><table-wrap-foot><p>* number of <italic>in silico</italic> prediction programs that predict pathogenicity/all applicable programs (SIFT, PolyPhen-2, AlignGVD, MutationTaster), ** highest minor allele frequency (MAF) of representative population – Exome Aggregation Consortium (ExAC) database, Exome Sequencing Project (ESP), or 1000 Genomes Project (1000G), *** based on ACMG recommendations, <italic>ACMG</italic> American College of Medical Genetics and Genomics, <italic>AR</italic> autosomal recessive, <italic>hem</italic> hemizygous, <italic>het</italic> heterozygous, <italic>hom</italic> homozygous, <italic>MAF</italic> minor allele frequency, <italic>OMIM</italic> Online Mendelian Inheritance in Man, <italic>XLR</italic> X-Linked Recessive</p></table-wrap-foot></table-wrap></p>
<p id="Par30">The c.325_339del (p.Val109_Ile113del) variant in the <italic>MFSD8</italic> gene was a previously unreported variant and found to be homozygous in our patient whereas his parents were heterozygote carriers (Table <xref ref-type="table" rid="Tab5">5</xref>). Segregation analysis of this variant was done in the affected index, his parents, and relatives. It is a deletion of 15 base pairs (bp), which causes the loss of five residues. The evolutionary conservation of amino acid residues in the region of deletion estimated by ConSurf tool [<xref ref-type="bibr" rid="CR29">29</xref>] is shown in Fig. <xref ref-type="fig" rid="Fig4">4</xref>.<fig id="Fig4"><label>Fig. 4</label><caption><p>The conservation scale adapted from the ConSurf Service. <ext-link ext-link-type="uri" xlink:href="http://consurf.tau.ac.il/2016/">http://consurf.tau.ac.il/2016/</ext-link>. Mutated domain highlighted in <italic>box</italic></p></caption><graphic id="MO4" xlink:href="13256_2018_1788_Fig4_HTML"></graphic></fig></p>
<p id="Par31">The c.259A&gt;G (p.Asn87Asp) variant found in <italic>AFF2</italic> was a hemizygous change in our patient; his mother was also heterozygous whereas his father was negative for this variant. This variant had not been reported in the public databases at the time of this publication (Table <xref ref-type="table" rid="Tab5">5</xref>).</p>
</sec>
<sec id="Sec3">
<title>Discussion</title>
<p id="Par32">The identified variant is a 15 bp in-frame deletion in <italic>MFSD8</italic> gene. Pathogenic variants in the <italic>MFSD8</italic> gene have been shown to be associated with AR NCL type 7. Visual loss and seizures may be the initial signs and symptoms. Epilepsy, ataxia, and myoclonus may be the initial features [<xref ref-type="bibr" rid="CR28">28</xref>] in children with age of onset after 4 years (Tables <xref ref-type="table" rid="Tab6">6</xref> and <xref ref-type="table" rid="Tab7">7</xref>). Segregation analysis in this family found 15 bp in-frame deletion in <italic>MFSD8</italic> gene which is compatible with disease (Fig. <xref ref-type="fig" rid="Fig3">3</xref>).<table-wrap id="Tab6"><label>Table 6</label><caption><p><italic>AFF2</italic> and <italic>MFSD8</italic> genes information and aliases</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Ensembl/OMIM ID/Gene Ontology/</th><th>Aliases</th><th>Location/Exon count</th><th>Function</th></tr></thead><tbody><tr><td>
<italic>MFSD8</italic>
<break></break>(NM_152778.2)</td><td>ENSG00000164073/<break></break>611,124/<break></break>GO:0007040<break></break>GO:0055085</td><td>Major facilitator superfamily domain-containing 8, <italic>CLN7</italic></td><td>4q28.2/<break></break>13 Exons</td><td>Transmembrane ubiquitous protein consists of major facilitator superfamily and transporter domains</td></tr><tr><td>
<italic>AFF2</italic>
<break></break>(NM_002025.3)</td><td>ENSG00000155966/<break></break>300,806/<break></break>GO:0002151</td><td><italic>AF4</italic>/<italic>FMR2</italic> family member 2,<break></break>fragile XE mental retardation syndrome protein,<break></break>fragile X mental retardation 2 protein,<break></break>protein FMR-2,<break></break><italic>FMR2P</italic>,<break></break><italic>FMR2</italic>,<break></break><italic>OX19</italic>, fragile X mental retardation 2, <italic>AF4</italic>/<italic>FMR2</italic> family member 2</td><td>Xq28/<break></break>22 Exons</td><td>G-quadruplex RNA binding, RNA splicing</td></tr></tbody></table><table-wrap-foot><p><italic>OMIM</italic> Online Mendelian Inheritance in Man</p><p>RNA Ribonucleic acid</p></table-wrap-foot></table-wrap><table-wrap id="Tab7"><label>Table 7</label><caption><p>Common reported mutations of <italic>AFF2</italic> and <italic>MFSD8</italic> genes, related signs and symptoms and disorders</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Common reported mutations</th><th>Signs and symptoms</th><th>Related disorders</th></tr></thead><tbody><tr><td>
<italic>MFSD8</italic>
<break></break>(NM_152778.2)</td><td>Missense and nonsense mutation, splice site mutation, frameshift, deletion</td><td>Seizures or motor impairment, mental regression, myoclonus seizure, speech impairment, loss of motor function and quadriplegia, early onset loss of vision, sleep disorders, loss of cognitive function</td><td>Ceroid lipofuscinosis, neuronal, 7</td></tr><tr><td>
<italic>AFF2</italic>
<break></break>(NM_002025.3)</td><td>Triple expansion of GCC to &gt; 200 in comparison with 6–25 normal copy number of GCC</td><td>Mild-to-moderate mental retardation, learning disabilities, communication problems, attention loss, hyperactivity, autistic behaviors, metabolic and homeostatic abnormalities</td><td>Fragile XE syndrome,<break></break>X-linked mental retardation associated with fragile site FRAXE,<break></break>FRAXE intellectual disability</td></tr></tbody></table><table-wrap-foot><p><italic>FRAXE</italic> fragile XE syndrome</p></table-wrap-foot></table-wrap></p>
<p id="Par33"><italic>MFSD8</italic> is located on chromosome 4q28.1-q28.2; it has 55,180 bp and 13 exons, encoding a 4562 bp transcript and a protein with 518 amino acids. Major facilitator superfamily domain-containing protein 8 which encoded by <italic>MFSD8</italic> is a transmembrane ubiquitous protein that consists of a major facilitator superfamily (MFS) and transporter domains [<xref ref-type="bibr" rid="CR27">27</xref>]. This protein locates into lysosomal membrane and acts as a multi-pass membrane protein using chemiosmotic ion gradients [<xref ref-type="bibr" rid="CR30">30</xref>]. Figure <xref ref-type="fig" rid="Fig5">5</xref> shows topological structure of MFSD8 wild type and mutant protein. The deletion found in this patient affects the exon 5 of this gene which is the region encoding transmembrane domain. According to IRANOME database (<ext-link ext-link-type="uri" xlink:href="http://www.iranome.ir">http://www.iranome.ir</ext-link>/), the mean allele frequency of this variant is unknown.<fig id="Fig5"><label>Fig. 5</label><caption><p>Front view and surface of MFSD8 protein. <bold>a</bold> Normal; <bold>b</bold> mutant. Structural topology has been changed in mutant form. Adapted from Yet Another Scientific Artificial Reality Application (YASARA)</p></caption><graphic id="MO5" xlink:href="13256_2018_1788_Fig5_HTML"></graphic></fig></p>
<p id="Par34">Based on the NCL mutation database held at the University College London, at the time of writing this manuscript, there were 38 reported mutations in <italic>MFSD8</italic> gene in different populations [<xref ref-type="bibr" rid="CR9">9</xref>]. The most common mutations are missense and nonsense mutations; however, other types of mutations such as splice site, single bp deletion, frameshift, and one case of 17 bp deletion are also reported [<xref ref-type="bibr" rid="CR28">28</xref>].</p>
<p id="Par35">Rare pathogenic variants in the AFF2 gene have been identified in patients with autism and attention deficit hyperactivity disorders as well as with X-linked intellectual disability and developmental and speech delay [<xref ref-type="bibr" rid="CR32">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. In addition, this gene has been associated with syndromic autism, where a subpopulation of individuals with a given syndrome develops autism. A rare pathogenic variant in the <italic>AFF2</italic> gene has been identified in patients with fragile X syndrome [<xref ref-type="bibr" rid="CR32">32</xref>]. Mondal <italic>et al.</italic> suggested that rare variants in <italic>AFF2</italic> may be the cause for previously unrecognized autism spectrum disorder (ASD) susceptibility locus and may help to explain some of the male excess of ASD [<xref ref-type="bibr" rid="CR33">33</xref>]. The other related phenotypes to <italic>AFF2</italic> gene are abnormality of metabolism/homeostasis [<xref ref-type="bibr" rid="CR34">34</xref>], aggressive behavior [<xref ref-type="bibr" rid="CR35">35</xref>], epicanthic fold, and delayed speech and development of language [<xref ref-type="bibr" rid="CR36">36</xref>].</p>
<p id="Par36"><italic>AFF2</italic> is a protein coding gene and member of the <italic>AF4</italic>\<italic>FMR2</italic> gene family which is located on chromosome Xq28. This ribonucleic acid (RNA)-binding protein is implicated in the splicing process. The trinucleotide repeat expansion of CCG at 5′ untranslated region (UTR) of <italic>AFF2</italic> causes fragile XE syndrome (FRAXE) [<xref ref-type="bibr" rid="CR37">37</xref>]. More details of this gene are included in Tables <xref ref-type="table" rid="Tab6">6</xref> and <xref ref-type="table" rid="Tab7">7</xref>. Although the hemizygous variant found in the affected male of this family segregates in the tested samples, based on the clinical symptoms of the affected male, this variant cannot explain the hallmark and pathognomonic characteristics observed in the affected male. So, based on the clinical findings, correlation of the <italic>AFF2</italic> variant with the disease in this family is very unlikely. Tables <xref ref-type="table" rid="Tab6">6</xref> and <xref ref-type="table" rid="Tab7">7</xref> summarize the expected and observed phenotypic symptoms.</p>
</sec>
<sec id="Sec4">
<title>Conclusions</title>
<p id="Par37">Sequencing analysis in this family has shown that the index is homozygous for 15 bp in-frame deletion, his uncle has normal homozygous, and his parents are heterozygous (Fig. <xref ref-type="fig" rid="Fig6">6</xref>).<fig id="Fig6"><label>Fig. 6</label><caption><p>Deoxyribonucleic acid sequence of mutated region. Normal homozygous uncle and heterozygous parents and homozygous patient for in-frame 15 base pairs deletion. <italic>bp</italic> base pairs</p></caption><graphic id="MO6" xlink:href="13256_2018_1788_Fig6_HTML"></graphic></fig></p>
<p id="Par38">This pattern of mutation inheritance and the signs and symptoms observed in the affected male of this family are compatible with what is described in the literature for NCL type 7 and, therefore, suggest that the <italic>MFSD8</italic> deletion found in this study is most probably the cause of disease in this family.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AR</term>
<def>
<p id="Par4">Autosomal recessive</p>
</def>
</def-item>
<def-item>
<term>ASD</term>
<def>
<p id="Par5">Autism spectrum disorder</p>
</def>
</def-item>
<def-item>
<term>bp</term>
<def>
<p id="Par6">Base pair</p>
</def>
</def-item>
<def-item>
<term>CCS</term>
<def>
<p id="Par7">Consensus Coding Sequences</p>
</def>
</def-item>
<def-item>
<term>CLNs or NCLs</term>
<def>
<p id="Par8">Neuronal ceroid lipofuscinoses</p>
</def>
</def-item>
<def-item>
<term>EEG</term>
<def>
<p id="Par9">Electroencephalogram</p>
</def>
</def-item>
<def-item>
<term>FRAXE</term>
<def>
<p id="Par10">Fragile XE syndrome</p>
</def>
</def-item>
<def-item>
<term>GC-MS</term>
<def>
<p id="Par11">Gas chromatography–mass spectrometry</p>
</def>
</def-item>
<def-item>
<term>INCL</term>
<def>
<p id="Par12">Infantile neuronal ceroid lipofuscinosis</p>
</def>
</def-item>
<def-item>
<term>JNCL</term>
<def>
<p id="Par13">Juvenile neuronal ceroid lipofuscinosis</p>
</def>
</def-item>
<def-item>
<term>LINCL</term>
<def>
<p id="Par14">Late infantile neuronal ceroid lipofuscinosis</p>
</def>
</def-item>
<def-item>
<term>MAF</term>
<def>
<p id="Par15">Minor allele frequency</p>
</def>
</def-item>
<def-item>
<term>Mb</term>
<def>
<p id="Par16">Mega base pairs</p>
</def>
</def-item>
<def-item>
<term>MFS</term>
<def>
<p id="Par17">Major facilitator superfamily</p>
</def>
</def-item>
<def-item>
<term>NCLs or CLNs</term>
<def>
<p id="Par18">Neuronal ceroid lipofuscinoses</p>
</def>
</def-item>
<def-item>
<term>
<italic>PPT</italic>
</term>
<def>
<p id="Par19">Palmitoyl-protein thioesterase</p>
</def>
</def-item>
<def-item>
<term>TPP1</term>
<def>
<p id="Par20">Tripeptidyl-peptidase 1</p>
</def>
</def-item>
<def-item>
<term>UTR</term>
<def>
<p id="Par21">Untranslated region</p>
</def>
</def-item>
<def-item>
<term>WES</term>
<def>
<p id="Par22">Whole exome sequencing</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgements</title>
<p>The Authors would like to give special thanks to the involved family who tightly collaborated with this report.</p>
<p>We are also grateful to Dr Ahmad Reza Salehi and Mr Ehsan Razmara for their assistance and valuable comments.</p>
<sec id="FPar1">
<title>Availability of data and materials</title>
<p id="Par39">Results of genetic analysis are included in this report.</p>
</sec>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>MG conducted the experiments. MG and AHB analysed the data. AHB contributed reagents/materials/analysis tools. MG and AHB wrote the paper. MG and AHB read and approved the final manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar2">
<title>Ethics approval and consent to participate</title>
<p>The involved family was informed about the benefits and consequence of genetics testing and a written consent letter was also obtained for their participation.</p>
</sec>
<sec id="FPar3">
<title>Consent for publication</title>
<p>Written informed consent was obtained from the patient’s legal guardian(s) for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
</sec>
<sec id="FPar4">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar5">
<title>Publisher’s Note</title>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<mixed-citation publication-type="other">Geraets RD, Koh SY, Hastings ML, Kielian T, Pearce DA, Weimer JM. Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis. Orphanet J. Rare Dis. 2016;11(1):40.</mixed-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bennett</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Rakheja</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The neuronal ceroid-lipofuscinoses</article-title>
<source/>Dev. Disabil. Res. Rev
          <year>2013</year>
<volume>17</volume>
<issue>3</issue>
<fpage>254</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1002/ddrr.1118</pub-id>
<pub-id pub-id-type="pmid">23798013</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jadav</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yasha</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Aravinda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gayathri</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bindu</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Satishchandra</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes</article-title>
<source/>Pediatr Neurol
          <year>2014</year>
<volume>50</volume>
<issue>1</issue>
<fpage>85</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2013.08.008</pub-id>
<pub-id pub-id-type="pmid">24120650</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albert</surname>
<given-names>D</given-names>
</name>
<name>
<surname>De Los</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Vidaurre</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>A case of neuronal Ceroid Lipofuscinosis masquerading as Panayiotopoulos syndrome</article-title>
<source/>J Pediatr Epilepsy
          <year>2016</year>
<volume>5</volume>
<issue>01</issue>
<fpage>047</fpage>
<lpage>052</lpage>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stogmann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>El Tawil</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wagenstaller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gaber</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Edris</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Abdelhady</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Assem-Hilger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Leutmezer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bonelli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Baumgartner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zimprich</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>A novel mutation in the <italic>MFSD8</italic> gene in late infantile neuronal ceroid lipofuscinosis</article-title>
<source/>Neurogenetics
          <year>2009</year>
<volume>10</volume>
<issue>1</issue>
<fpage>73</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-008-0153-1</pub-id>
<pub-id pub-id-type="pmid">18850119</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mink</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Augustine</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Classification and natural history of the neuronal ceroid lipofuscinoses</article-title>
<source/>J Child Neurol
          <year>2013</year>
<volume>9</volume>
<fpage>0883073813494268</fpage>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haltia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Goebel</surname>
<given-names>HH</given-names>
</name>
</person-group>
<article-title>The neuronal ceroid-lipofuscinoses: a historical introduction</article-title>
<source/>Biochim Biophys Acta
          <year>2013</year>
<volume>1832</volume>
<issue>11</issue>
<fpage>1795</fpage>
<lpage>1800</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2012.08.012</pub-id>
<pub-id pub-id-type="pmid">22959893</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Goebel</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Mole</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Lake</surname>
<given-names>BD</given-names>
</name>
</person-group>
<source/>The neuronal ceroid lipofuscinoses (Batten disease)
          <year>1999</year>
<publisher-loc>Amsterdam</publisher-loc>
<publisher-name>IOS Press</publisher-name>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<mixed-citation publication-type="other">NCL mutation database. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.ucl.ac.uk/ncl/SummaryTableMay2015.htm">https://www.ucl.ac.uk/ncl/SummaryTableMay2015.htm</ext-link>.</mixed-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warrier</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mole</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Genetic basis and phenotypic correlations of the neuronal ceroid lipofuscinoses</article-title>
<source/>Biochim Biophys Acta
          <year>2013</year>
<volume>1832</volume>
<issue>11</issue>
<fpage>1827</fpage>
<lpage>1830</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2013.03.017</pub-id>
<pub-id pub-id-type="pmid">23542453</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sleat</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Gin</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Sohar</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sklower-Brooks</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pullarkat</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Lerner</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Boustany</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Uldall</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Siakotos</surname>
<given-names>AN</given-names>
</name>
</person-group>
<article-title>Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder</article-title>
<source/>Am J Hum Genet
          <year>1999</year>
<volume>64</volume>
<issue>6</issue>
<fpage>1511</fpage>
<lpage>1523</lpage>
<pub-id pub-id-type="doi">10.1086/302427</pub-id>
<pub-id pub-id-type="pmid">10330339</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mole</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Goebel</surname>
<given-names>HH</given-names>
</name>
</person-group>
<article-title>Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses</article-title>
<source/>Neurogenetics
          <year>2005</year>
<volume>6</volume>
<issue>3</issue>
<fpage>107</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-005-0218-3</pub-id>
<pub-id pub-id-type="pmid">15965709</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jalanko</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Braulke</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Neuronal ceroid lipofuscinoses</article-title>
<source/>Biochim Biophys Acta
          <year>2009</year>
<volume>1793</volume>
<issue>4</issue>
<fpage>697</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2008.11.004</pub-id>
<pub-id pub-id-type="pmid">19084560</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sleat</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Donnelly</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Lackland</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Sohar</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pullarkat</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Lobel</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis</article-title>
<source/>Science
          <year>1997</year>
<volume>277</volume>
<issue>5333</issue>
<fpage>1802</fpage>
<lpage>1805</lpage>
<pub-id pub-id-type="doi">10.1126/science.277.5333.1802</pub-id>
<pub-id pub-id-type="pmid">9295267</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nita</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Mole</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Minassian</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Neuronal ceroid lipofuscinoses</article-title>
<source/>Epileptic Disord
          <year>2016</year>
<volume>18</volume>
<issue>s2</issue>
<fpage>73</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="pmid">27629553</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Götzl</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Damme</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fellerer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tahirovic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kleinberger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Janssens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van der Zee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Kremmer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis</article-title>
<source/>Acta Neuropathol
          <year>2014</year>
<volume>127</volume>
<issue>6</issue>
<fpage>845</fpage>
<lpage>860</lpage>
<pub-id pub-id-type="pmid">24619111</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karaa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Simas</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>John</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Glykys</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Cotman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>KB</given-names>
</name>
</person-group>
<article-title>Expanding the clinical spectrum of the lysosomal disorders with whole exome sequencing</article-title>
<source/>Abstracts/Mol. Genet. Metab
          <year>2015</year>
<volume>114</volume>
<fpage>S11</fpage>
<lpage>S30</lpage>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mercimek-Mahmutoglu</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Epileptic encephalopathy in childhood: a stepwise approach for identification of underlying genetic causes</article-title>
<source/>Indian J. Pediatr
          <year>2016</year>
<volume>83</volume>
<issue>10</issue>
<fpage>1164</fpage>
<lpage>1174</lpage>
<pub-id pub-id-type="doi">10.1007/s12098-015-1979-9</pub-id>
<pub-id pub-id-type="pmid">26821542</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>García-Cazorla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>NI</given-names>
</name>
<name>
<surname>Mochel</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>GF</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Hoffman</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Zschocke</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nyhan</surname>
<given-names>WL</given-names>
</name>
</person-group>
<article-title>Neurological disease</article-title>
<source/>Inherited metabolic diseases: A clinical approach
          <year>2017</year>
<publisher-loc>Berlin Heidelberg</publisher-loc>
<publisher-name>Springer</publisher-name>
<fpage>251</fpage>
<lpage>292</lpage>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Langereis</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Wijburg</surname>
<given-names>FA</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Boelens</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Wynn</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Lysosomal diseases and therapeutic options: an overview</article-title>
<source/>Stem cell therapy in Lysosomal storage diseases
          <year>2013</year>
<publisher-loc>New York</publisher-loc>
<publisher-name>Springer</publisher-name>
<fpage>1</fpage>
<lpage>20</lpage>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>RE</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Mehta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Winchester</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Neuronal Ceroid Lipofuscinoses</article-title>
<source/>Lysosomal Storage Disorders: A Practical Guide
          <year>2012</year>
<fpage>137</fpage>
<lpage>141</lpage>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Järvelä</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Schleutker</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Haataja</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Santavuori</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Puhakka</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Manninen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Palotie</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sandkuijl</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Renlund</surname>
<given-names>M</given-names>
</name>
<name>
<surname>White</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Aula</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Infantile form of neuronal ceroid lipofuscinosis (CLN1) maps to the short arm of chromosome 1</article-title>
<source/>Genomics
          <year>1991</year>
<volume>9</volume>
<issue>1</issue>
<fpage>170</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1016/0888-7543(91)90235-7</pub-id>
<pub-id pub-id-type="pmid">1672288</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grisolia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sestito</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ceravolo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Invernizzi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Salpietro</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Polizzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ruggieri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Garavaglia</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Concolino</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The neuronal Ceroid Lipofuscinoses: a case-based overview</article-title>
<source/>J Pediatr Biochemistry
          <year>2016</year>
<volume>6</volume>
<issue>01</issue>
<fpage>060</fpage>
<lpage>065</lpage>
<pub-id pub-id-type="doi">10.1055/s-0036-1582222</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahmood</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cooke</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>A zebrafish model of CLN2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation</article-title>
<source/>Brain
          <year>2013</year>
<volume>136</volume>
<fpage>1488</fpage>
<lpage>1507</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awt043</pub-id>
<pub-id pub-id-type="pmid">23587805</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minye</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Fabritius</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Vesa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Peltonen</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Data on characterizing the gene expression patterns of neuronal ceroid lipofuscinosis genes: <italic>CLN1</italic>, <italic>CLN2</italic>, <italic>CLN3</italic>, <italic>CLN5</italic> and their association to interneuron and neurotransmission markers: Parvalbumin and Somatostatin</article-title>
<source/>Data in Brief
          <year>2016</year>
<volume>8</volume>
<fpage>741</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="doi">10.1016/j.dib.2016.06.027</pub-id>
<pub-id pub-id-type="pmid">27508227</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Mole</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>RE</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Panayiotopoulos</surname>
<given-names>CP</given-names>
</name>
</person-group>
<article-title>The neuronal Ceroid Lipofuscinoses</article-title>
<source/>Atlas of epilepsies
          <year>2010</year>
<publisher-loc>London</publisher-loc>
<publisher-name>Springer</publisher-name>
<fpage>1235</fpage>
<lpage>41</lpage>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kashyap</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>McCue</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Edmonds</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Ayala</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Jenn</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Barclay</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Burgoyne</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title><italic>Caenorhabditis elegans dnj-14</italic>, the orthologue of the <italic>DNAJC5</italic> gene mutated in adult onset neuronal ceroid lipofuscinosis, provides a new platform for neuroprotective drug screening and identifies a SIR-2.1-independent action of resveratrol</article-title>
<source/>Human Molecular Genetics
          <year>2014</year>
<volume>23</volume>
<fpage>5916</fpage>
<lpage>5927</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu316</pub-id>
<pub-id pub-id-type="pmid">24947438</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Craiu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dragostin</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Dica</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hoffman-Zacharska</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bastian</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Gherghiceanu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rolfs</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nahavandi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Craiu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iliescu</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Rett-like onset in late-infantile neuronal ceroid lipofuscinosis (CLN7) caused by compound heterozygous mutation in the <italic>MFSD8</italic> gene and review of the literature data on clinical onset signs</article-title>
<source/>Eur J Paediatr Neurol
          <year>2015</year>
<volume>19</volume>
<issue>1</issue>
<fpage>78</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2014.07.008</pub-id>
<pub-id pub-id-type="pmid">25439737</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashkenazy</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Erez</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Martz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pupko</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ben-Tal</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids</article-title>
<source/>Nucleic Acids Res
          <year>2010</year>
<volume>38</volume>
<fpage>W529</fpage>
<lpage>W533</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkq399</pub-id>
<pub-id pub-id-type="pmid">20478830</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aiello</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Terracciano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Simonati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Discepoli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cannelli</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Claps</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Crow</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kitzmuller</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tavoni</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Mutations in <italic>MFSD8</italic>/<italic>CLN7</italic> are a frequent cause of variant-late infantile neuronal ceroid lipofuscinosis</article-title>
<source/>Hum Mutat
          <year>2009</year>
<volume>30</volume>
<issue>3</issue>
<fpage>E530</fpage>
<lpage>E540</lpage>
<pub-id pub-id-type="doi">10.1002/humu.20975</pub-id>
<pub-id pub-id-type="pmid">19177532</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abrams</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Doheny</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Mazzocco</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Baumgardner</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Freund</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Reiss</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Cognitive, behavioral, and neuroanatomical assessment of two unrelated male children expressing FRAXE</article-title>
<source/>Am J Med Genet
          <year>1997</year>
<volume>74</volume>
<issue>1</issue>
<fpage>73</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19970221)74:1&lt;73::AID-AJMG16&gt;3.0.CO;2-O</pub-id>
<pub-id pub-id-type="pmid">9034011</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bensaid</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Melko</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bechara</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Davidovic</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Berretta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Catania</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Gecz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lalli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bardoni</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>FRAXE-associated mental retardation protein (FMR2) is an RNA-binding protein with high affinity for G-quartet RNA forming structure</article-title>
<source/>Nucleic Acids Research
          <year>2009</year>
<volume>37</volume>
<fpage>1269</fpage>
<lpage>1279</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkn1058</pub-id>
<pub-id pub-id-type="pmid">19136466</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mondal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ramachandran</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Hagen</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Bose</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cutler</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Zwick</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Excess variants in <italic>AFF2</italic> detected by massively parallel sequencing of males with autism spectrum disorder</article-title>
<source/>Hum Mol Genet
          <year>2012</year>
<volume>21</volume>
<issue>19</issue>
<fpage>4356</fpage>
<lpage>4364</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/dds267</pub-id>
<pub-id pub-id-type="pmid">22773736</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Weinstein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>P</given-names>
</name>
<collab>Sigma-Aldrich Co</collab>
</person-group>
<source/>Genomic editing of genes involved in autism spectrum disorders
          <year>2010</year>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Todorova</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Litvinenko</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Todorov</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tincheva</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Avdjieva</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tincheva</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mitev</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>A family with fragile X syndrome, Duchenne muscular dystrophy and ichthyosis transmitted by an asymptomatic carrier</article-title>
<source/>Clin Genet
          <year>2014</year>
<volume>85</volume>
<issue>3</issue>
<fpage>286</fpage>
<lpage>289</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12148</pub-id>
<pub-id pub-id-type="pmid">23574351</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahoo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Theisen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marble</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tervo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Torchia</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Shaffer</surname>
<given-names>LG</given-names>
</name>
</person-group>
<article-title>Microdeletion of Xq28 involving the <italic>AFF2</italic> (<italic>FMR2</italic>) gene in two unrelated males with developmental delay</article-title>
<source/>Am J Med Genet A
          <year>2011</year>
<volume>155</volume>
<issue>12</issue>
<fpage>3110</fpage>
<lpage>3115</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.34345</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santos</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Lima</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pimentel</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>A new PCR assay useful for screening of FRAXE/FMR2 mental impairment among males</article-title>
<source/>Hum Mutat
          <year>2001</year>
<volume>18</volume>
<issue>2</issue>
<fpage>157</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="doi">10.1002/humu.1165</pub-id>
<pub-id pub-id-type="pmid">11462240</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>